IDO1 involvement in mTOR pathway: A molecular mechanism of resistance to mTOR targeting in medulloblastoma

Oncotarget

Volumn 7, Issue 33, 2016, Pages 52900-52911

  Folgiero, Valentina ^a   Miele, Evelina ^b,c   Carai, Andrea ^a   Ferretti, Elisabetta ^b   Alfano, Vincenzo ^b,c   Po, Agnese ^b   Bertaina, Valentina ^a   Goffredo, Bianca Maria ^a   Benedetti, Maria Chiara ^a   Camassei, Francesca Diomedi ^a   Cacchione, Antonella ^a   Locatelli, Franco ^a,d   Mastronuzzi, Angela ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

CCL2; IDO1; MB; MTOR; Treg

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; ANTINEOPLASTIC ANTIBIOTIC; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CANCER RESISTANCE; CELL EXPANSION; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INFANT; MEDULLOBLASTOMA; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; TUMOR ESCAPE; CEREBELLUM TUMOR; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; CHILD; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFANT; MEDULLOBLASTOMA; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; SIROLIMUS; T-LYMPHOCYTES, REGULATORY; TOR SERINE-THREONINE KINASES; TUMOR MICROENVIRONMENT;

EID: 84982275958     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9284     Document Type: Article

References (36)

1. Crawford JR, MacDonald TJ, Packer RJ. Medulloblastoma in childhood: new biological advances. Lancet Neurol. 2007; 12:1073-1085.
2. Northcott PA, Korshunov A, Pfister SM, Taylor MD. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol. 2012; 6:340-351.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 2:97-109.
4. Gupta T, Shirsat N, Jalali R. Molecular subgrouping of Medulloblastoma: impact upon research clinical practice. Curr Pediatr Rev. 2015; 2:106-119.
5. Cox MC, Kusters JM, Gidding CE, Schieving JH, van Lindert EJ, Kaanders JH, Janssens GO. Acute toxicity profile of craniospinal irradiation with intensity-modulated radiation therapyn in children with medulloblastoma: A prospective analysis. Radiat Oncol. 2015; 1:241.
6. MacDonald TJ, Agiulera D, Castellino RC. The rationale for targeted terapies in medulloblastoma. Neuro Oncol. 2014; 1:9-20.
7. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3K and mTOR signaling pathways in cancer: new data onmtargeted terapie. Curr Oncol Rep. 2012; 2:129-138.
8. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8:627-644.
9. Hartmann W, Digon-Sontgerath B, Koch A, Waha A, Endl E, Dani I, Denkhaus D, Goodyer CG, Sörensen N, Wiestler OD, Pietsch T. Phosphatidylinositol 3'-kinase/ AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res. 2006; 10:3019-3027.
10. Moavero R, Folgiero V, Carai A, Miele E, Ferretti E, Po A, Diomedi Camassei F, Lepri FR, Vigevano F, Curatolo P, Valeriani M, Colafati GS, Locatelli F, et al. Metastatic Group 2 Medulloblastoma in a patient with Tuberous Sclerosis Complex: case description and molecular characterization of the tumor. Pediatr Blood Cancer. 2015; doi:10.1002/pbc.25851.
11. Pòcza T, Sebestyén A, Turànyi E, Krenàcs T, Màrk A, Sticz TB, Jakab Z, Hauser P. mTOR pathway as a potential target in a subset of human medulloblastoma. Pathol Oncol Res. 2014; 4:893-900.
12. McGaha TL, Huang L, Lemos H, Metz R, Mautino M, Prendergast GC, Mellor AL. Amino acid catabolism: a pivotal regulation of innate and adaptive immunity. Immunol Rev. 2012; 1:135-137.
13. Prendergast GC, Smith C, Thomas S, Mandik-Navak L, Laury-Kleintop L, Metz R, Muller AJ al. Indoleamine 2, 3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother. 2014; 7:721-735.
14. Van Baren N, Van den Eynde BJ. Tryptophan-degrading enzymes in tumoral immune resi stance. Front Immunol. 2015; 3:34.
15. Lob S, Konigsrainer A, Zieker D, Brucher BL, Rammensee HG, Opelz G, Terness P. IDO1 and IDO2 are espresse in human tumors: levo-but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother. 2009; 1:153-7.
16. Wainwringht DA, Dey M, Chang A, Lesniak MS. Targeting Tregs in malignant brain cancer: overcoming IDO. Front Immunol. 2013; 4:116.
17. Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, Link CJ, Prendergast GC. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector patta targeted by D-1-methyl-truptophan. Oncoimmunology. 2012; 9:1460-1468.
18. Folgiero V, Goffredo BM, Filippini P, Masetti R, Bonanno G, Caruso R, Bertaina V, Mastronuzzi A, Gaspari S, Zecca M, Torelli GF, Testi AM, Pession A, et al. Indoleamine 2, 3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor out come in childhood acute myeloid leukemia. Oncotarget. 2014; 8:2052-2064. doi: 10.18632/ oncotarget.1504.
19. Valmori D, Tosello V, Souleimanian NE, Godefroy E, Scotto L, wang Y, Ayyoub M. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol. 2006; 2:944-949.
20. Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, Aboody KS, Jensen MC. Tumor-derived chemokine MCP-1/ CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol. 2007; 5:3332-3341.
21. Prendergast GC, Metz R, Muller AJ. Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. Am J Pathol. 2010; 5:2082-2087.
22. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene. 2008; 28:3889-3900.
23. Lin W, Kemper A, McCarthy KD, Pytel P, Wang JP, Campbell IL, Utset MF, Popko B. Interferon-gamma induced medulloblastoma in the developing cerebellum. J Neurosci. 2004; 45:10074-10083.
24. Thomson AW, Turnquist HR, Raimondi G. Immunoregolatory functions of mTOR inhibition. Nat rev Immunol. 2009; 5:324-327.
25. Guessous F, Li Y, Abounader R. Signaling pathways in medulloblastoma. J Cell Physiol. 2008; 3:577-583.
26. Platten M, von Knebel Doeberitz N, Oezen I, Wick W, Ochs K. Cancer Immunotherapy by targeting IDO1/TDO and their downstream effectors. Front Immunol. 2015; 9:537-545.
27. Coenen JJ, Koenen HJ, van Rijssen E, Kasran A, Boon L, Hilbrands LB, Joosten I. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+CD25+FoxP3+T cells. Bone Marrow Transplant. 2007; 9:537-545.
28. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, Servillo G, Brunacci C, Calvitti M, Bicciato S, Mazza EM, Boon L, Grassi F, et al. Indoleamine 2, 3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol. 2011; 12:870-878.
29. Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR, Hirahara K, Sun HW, Wei L, Vahedi G, Kanno Y, O'Shea JJ, Laurence A. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol. 2011; 3:247-254.
30. Soliman HH, Antonia S, Sullivan D, Vanahanian N, Link C. Overcoming tumor antigen anergy in human malignancies using the novel indoleamine2, 3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptofan (1-MT). Asco Meet Abstr. 2009; 27:3004.
31. Mastronuzzi A, Miele E, Po A, Antonelli M, Buttarelli FR, Colafati GS, del Bufalo F, Faedda R, Spinelli GP, Carai A, Giangaspero F, Gulino A, Locatelli F, et al. Large cell anaplastic medulloblastoma metastatic to the scalp: tumor and derived stem-like cells features. BMC. 2015; 3:13.
32. Miele E, Buttarelli FR, Arcella A, Begalli F, Garg N, Silvani M. High-throughput microRNA profiling of pediatric high grade gliomas. Neuro Oncol. 2014; 2:228-240.
33. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, Mrsic A, Ylstra B, Grajkowska W et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. Plos One. 2008; 8:e3088.
34. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, Phoenix TN, Hedlund E, Wei L, Zhu X, Chalhoub N, Baker SJ, Huether R et al. Novel mutations target distinct subgroups of medulloblastoma. Nature. 2012; 7409:43-48.
35. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, Stütz AM, Korshunov A, Reimand J, Schumacher SE, Beroukhim R, Ellison DW, Marshall CR et al. Subgroup-specific structural variation across 1, 000 medulloblastoma genomes. Nature. 2012; 7409:49-56.
36. Miele E, Buttarelli FR, Arcella A, Begalli F, Garg N, Silvano M, Po A, Baldi C, Carissimo G, Antonelli M, Spinelli GP, Capalbo C, Donofrio V, et al. High-throughput microRNA profiling of pediatric high-grade gliomas. Neuro Oncol. 2014; 2:228-240.